Profile data is unavailable for this security.
About the company
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.
- Revenue in USD (TTM)48.63bn
- Net income in USD-1.66bn
- Incorporated--
- Employees104.71k
- LocationBayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
- Phone+49 214301
- Fax+49 2 143066328
- Websitehttps://www.bayer.de/
More ▼
Mergers & acquisitions
| Acquired company | BAYX.N:GER since announced | Transaction value |
|---|---|---|
| Bluerock Therapeutics LP | 27.89% | 600.00m |
| Maty's Healthy Products LLC | 26.45% | -- |
Data delayed at least 15 minutes, as of Jan 17 2020 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 17.36bn | 1.27bn | 16.55bn | 54.04k | 44.03 | 2.83 | 5.13 | 0.9534 | 2.62 | 7.96 | 35.98 | 41.76 | 0.4025 | 1.94 | 4.86 | 302,786.50 | 2.96 | 4.54 | 3.90 | 5.98 | 63.13 | 66.09 | 7.35 | 11.03 | 1.08 | 5.40 | 0.4083 | 9.90 | 2.20 | 5.98 | -57.97 | -2.28 | 14.48 | 5.64 |
| Shionogi & Co Ltd | 3.24bn | 1.15bn | 20.49bn | 5.23k | 17.58 | 3.23 | 15.57 | 6.33 | 405.18 | 405.18 | 1,141.93 | 2,208.95 | 0.4679 | 1.44 | 7.66 | 68,105,300.00 | 16.61 | 13.21 | 18.43 | 15.07 | 83.71 | 77.72 | 35.49 | 26.76 | 6.31 | -- | 0.0011 | 26.56 | 5.53 | 4.65 | 21.95 | 26.73 | -12.11 | 15.36 |
| Otsuka Holdings Co Ltd | 12.46bn | 1.06bn | 24.85bn | 32.94k | 23.57 | 1.54 | 14.41 | 1.99 | 208.24 | 208.24 | 2,532.43 | 3,189.11 | 0.5289 | 2.70 | 3.74 | 41,677,970.00 | 4.63 | -- | 5.68 | -- | 67.28 | -- | 8.75 | -- | 1.95 | -- | 0.1572 | -- | 4.20 | -- | -26.67 | -- | -- | -- |
| Alexion Pharmaceuticals, Inc. | 4.74bn | 1.36bn | 25.07bn | 2.66k | 18.77 | 2.42 | 14.36 | 5.29 | 6.04 | 6.53 | 21.07 | 46.85 | 0.3305 | 0.747 | 4.67 | 1,782,982.00 | 9.50 | 3.24 | 10.25 | 3.51 | 92.04 | 90.43 | 28.73 | 10.96 | 3.45 | 23.89 | 0.2013 | 0.00 | 16.34 | 21.64 | -95.69 | -39.15 | 48.67 | -- |
| Astellas Pharma Inc | 11.89bn | 2.24bn | 32.78bn | 16.24k | 14.72 | 2.78 | 11.66 | 2.76 | 129.85 | 129.85 | 689.28 | 687.45 | 0.6774 | 1.93 | 3.98 | 80,633,010.00 | 12.77 | 10.34 | 16.82 | 13.43 | 78.06 | 75.90 | 18.85 | 14.30 | 1.46 | -- | 0.1135 | 37.46 | 0.4639 | 2.76 | 34.97 | 19.59 | -1.47 | 7.07 |
| Chugai Pharmaceutical Co Ltd | 6.01bn | 1.27bn | 53.68bn | 7.43k | 41.50 | 7.11 | -- | 8.93 | 254.58 | 254.58 | 1,208.13 | 1,485.30 | 0.6912 | 1.62 | 3.58 | 89,100,910.00 | 14.57 | 8.40 | 17.35 | 9.93 | 59.25 | 52.32 | 21.08 | 13.07 | 2.80 | -- | 0.00 | 50.53 | 8.53 | 6.48 | 27.20 | 12.69 | 39.01 | 9.86 |
| Takeda Pharmaceutical Co Ltd | 26.12bn | 142.00m | 63.44bn | 49.58k | 138.09 | 1.42 | 12.65 | 2.43 | 32.10 | 32.10 | 2,130.24 | 3,123.56 | 0.3354 | 1.86 | 4.64 | 58,025,380.00 | 0.1843 | 1.36 | 0.2155 | 1.77 | 65.22 | 69.83 | 0.5494 | 3.83 | 0.9382 | 0.4714 | 0.5078 | 226.33 | 18.45 | 4.39 | -41.61 | 0.4586 | 11.30 | 0.00 |
| Bayer AG (ADR) | 48.63bn | -1.66bn | 82.32bn | 104.71k | -- | 1.53 | 20.73 | 1.69 | -0.4237 | -0.3594 | 12.39 | 13.66 | 0.3357 | 1.73 | 3.74 | 415,634.60 | -1.14 | 4.12 | -1.39 | 5.28 | 57.42 | 58.83 | -3.39 | 8.16 | 0.8826 | 4.11 | 0.4869 | 69.67 | 13.05 | -0.286 | -47.83 | -11.87 | 3.75 | -- |
| Novartis AG | 49.56bn | 7.21bn | 243.10bn | 109.00k | 31.02 | 4.15 | 18.97 | 4.90 | 3.00 | 4.91 | 20.62 | 22.45 | 0.3829 | 2.21 | 6.04 | 383,391.80 | 5.57 | 6.81 | 7.13 | 8.41 | 70.90 | 66.55 | 14.55 | 17.42 | 0.7283 | 57.90 | 0.3641 | 74.61 | 6.05 | 0.1702 | 65.02 | 6.53 | -0.1366 | 0.9933 |
Data as of Jan 17 2020. Currency figures normalised to Bayer AG's reporting currency: US Dollar USD
0.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Parametric Portfolio Associates LLCas of 30 Sep 2019 | 2.61m | 0.07% |
| Academy Capital Management, Inc.as of 30 Sep 2019 | 969.15k | 0.03% |
| Pacer Advisors, Inc.as of 30 Sep 2019 | 399.99k | 0.01% |
| AMG National Trust Bankas of 30 Sep 2019 | 184.24k | 0.01% |
| Tocqueville Asset Management LPas of 31 Dec 2019 | 177.20k | 0.01% |
| Pillar Pacific Capital Management LLCas of 30 Sep 2019 | 116.88k | 0.00% |
| DWS Investment Management Americas, Inc.as of 30 Nov 2019 | 111.01k | 0.00% |
| Cheviot Value Management LLCas of 30 Sep 2019 | 100.67k | 0.00% |
| Strategic Advisers LLCas of 30 Nov 2019 | 88.63k | 0.00% |
| Ally Financial, Inc. (Investment Management)as of 30 Sep 2019 | 75.00k | 0.00% |
More ▼
Data from 30 Sep 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
